Conditions: Metastatic Renal Cell Carcinoma Metastatic Melanoma
Keywords: Metastatic Renal Cell Carcinoma Metastatic Melanoma Aldesleukin IL-2
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 26
Healthy volunteers: no

Brief summary:
This study evaluated the pharmacokinetics of aldesleukin in participants with metastatic renal cell cancer or metastatic melanoma.

Detailed description:

Arms:
arm 1: All participants were treated with aldesleukin 600,000 international units per kilogram \[IU/kg\] (0.037 milligram (mg)/kg) administered as a 15-minute intravenous (IV) infusion every 8 hours for a maximum of 14 doses for the first cycle (5-day cycle). Following 9 days of rest from therapy, the cycle was repeated for up to 14 doses (i.e., a total of up to 28 doses), if tolerated.

Interventions: intervention 1: Aldesleukin
Intervention descriptions: intervention 1: None

Protocol document: